Federal Register / Vol. 76, No. 76 / Wednesday, April 20, 2011 / Notices 22109 

Dated: April 13, 2011. 

Vivian Horovitch-Kelley, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. 2011–9509 Filed 4–19–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

NAG–1 Transgenic Mouse Model 

Description of Technology: The 

nonsteroidal anti-inflammatory drugactivated gene-1 (NAG–1) encodes a 

protein that has anti-inflammatory, 

proapoptotic, and antitumor properties. 

It plays a pivotal role in 

antitumorigenesis induced by 

chemopreventive compounds. 

Transgenic mice expressing human 

NAG–1 have been developed by the NIH 

investigator and collaborator. 

The NAG–1 transgenic mice are 

shown to develop few tumors in 

response to carcinogenic stimuli than 

wild type mice. They are also leaner 

with less fat than their wild type 

counterparts. As such, these mice can be 

used to investigate the development of 

cancers, and they could be of value in 

studying obesity and the relationship to 

cancer risk, and inflammation. 

Inventors: Thomas E. Eling (NIEHS), 

et al. 

Publications: 

1. Baek SJ, Okazaki R, Lee SH, Martinez J, 

Kim JS, Yamaguchi K, Mishina Y, Martin 

DW, Shoieb A, McEntee MF, Eling TE. 

Nonsteroidal anti-inflammatory drug 

activated gene-1 overexpression in 

transgenic mice suppresses intestinal 

neoplasia. Gastroenterology. 2006 

Nov;131(5):1553–1560. [PubMed: 

17101328] 

2. Cekanova M, Lee SH, Donnell RL, 

Sukhthankar M, Eling TE, Fischer SM, 

Baek SJ. Nonsteroidal anti-inflammatory 

drug-activated gene-1 expression inhibits 

urethane-induced pulmonary 

tumorigenesis in transgenic mice. Cancer 

Prev Res (Phila). 2009 May;2(5):450–458. 

[PubMed: 19401523] 

Patent Status: HHS Reference No. E– 

093–2011/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for 

licensing under a Biological Materials 

License Agreement. 

Licensing Contact: Betty B. Tong, 

PhD; 301–594–6565; 

tongb@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIEHS is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. Please 

contact Elizabeth M. Denholm, NIEHS 

Office of Technology Transfer, 

denholme@niehs.nih.gov, 919–541– 

0981, for more information. 

Altered miRNA Expression as 

Diagnostics and Therapeutics for 

Adrenocortical Carcinomas 

Description of Technology: This 

technology describes that altered human 

miRNA expression such as miRNA–483 

and miRNA 100 can accurately predict 

if a patient’s adrenal cortex tumor is 

benign or malignant. Adrenocortical 

carcinomas (ACC) are rare but 

aggressive cancers and typically have a 

poor prognosis. Currently, there are 

limited options for molecular diagnosis 

to distinguish malignant tumors from 

benign tumors of this type. As a result 

there are few treatment strategies for 

ACC. 

Additionally, preliminary results 

suggest that altering the expression of 

this miRNA in ACC cells can effect 

cancer cell growth. Therefore, inhibiting 

a miRNA may serve as a therapeutic 

option for ACC. 

Applications: 

• Technology can be developed into a 

diagnostic and prognostic marker for 

ACC. 

• Inhibiting miRNA can serve as a 

potential therapeutics for ACC. 

Advantages: 

• Distinguishes malignant Adrenal 

cortex tumor from a benign tumor, 

options for such distinction are limited 

at this time. 

• Technology can help in increased 

and improved diagnosis and therapeutic 

options for ACC. 

Development Status: 

• Pre-clinical. 

• Clinical study to test the markers in 

biopsy and serum samples being 

planned. 

Inventors: Electron Kebebew (CCR, 

NCI) and Erin E. Patterson (CCR, NCI) 

Publication: Patterson E. E. et al. 

(Cancer, 2010). [PubMed: 21061324] 

Patent Status: U.S. Provisional 

Application No. 12/961,298 filed 

December 6, 2010 (HHS Reference No. 

E–026–2011/0–US–01) 

Licensing Status: Available for 

licensing. 

Licensing Contact: Sabarni Chatterjee, 

PhD, M.B.A.; 301–435–5587; 

chatterjeesa@mail.nih.gov 

Collaborative Research Opportunity: 

The Center for Cancer Research, Surgery 

Branch, is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize the use of diagnostic 

miRNAs and to target these miRNAs for 

treatment. Please contact John Hewes, 

PhD at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Novel Inhibitors of Thymic Stromal 

Lymphopoietin (TSLP) for Cancer 

Therapy 

Description of Technology: With 

estimated overall costs in the U.S. in 

2006 at $206.3 billion and WHO 

predictions of 15 million new cases 

globally by 2020, the overall economic 

cost of cancer is staggering. There 

remains a significant unmet need for 

therapies to control the spread 

(metastasis) of cancers to other organs in 

the body. Available for licensing are 

compositions and methods of using 

antagonists of thymic stromal 

lymphopoietin (TSLP) to prevent cancer 

progression and metastasis. 

TSLP, an IL–7-like type 1 

inflammatory cytokine that is often 

associated with the induction of Th2- 

type allergic responses in the lungs, is 

also expressed in cancers regulating 

their escape (1–3). The cancerpromoting activity of TSLP primarily 

required signaling through the TSLP 

receptor on CD4+ T cells, promoting 

Th2-skewed immune responses and 

production of immunosuppressive 

factors such as IL–10 and IL–13. 

Expression of TSLP therefore may be a 

useful prognostic marker and its 


srobinson on DSKHWCL6B1PROD with NOTICES
22110 Federal Register / Vol. 76, No. 76 / Wednesday, April 20, 2011 / Notices 

targeting could have therapeutic 

potential. Inactivation of TSLP 

expression or its receptor signaling can 

effectively control cancer progression 

and metastasis (1). 

Applications: 

• In treatments to control cancer 

invasion and spreading 

• Cancer treatment that circumvents 

cancer-induced immune suppression 

• As a means to augment anti-tumor 

immune responses 

• For the development of prognostic 

markers for disease outcome in cancer 

patients 

Inventors: Arya Biragyn (NIA), Warren 

J. Leonard (NHLBI) 

Relevant Publications: 

1. Olkhanud PB, Rochman Y, Bodogai 

M, Malchinkhuu E, Wejksza K, Xu M, 

Gress RE, Hesdorffer C, Leonard WJ, 

Biragyn A. Thymic stromal 

lymphopoietin is a key mediator of 

breast cancer progression. J Immunol. 

2011;V:186, In Press. 

2. De Monte L, Reni M, Tassi E, 

Clavenna D, Papa I, Recalde H, Braga M, 

Di Carlo V, Doglioni C, Protti MP. 

Intratumor T helper type 2 cell infiltrate 

correlates with cancer-associated 

fibroblast thymic stromal lymphopoietin 

production and reduced survival in 

pancreatic cancer. J Exp Med. 2011 Mar 

14;208(3):469–478. [PubMed: 21339327] 

3. Pedroza-Gonzalez A, Xu K, Wu TC, 

Aspord C, Tindle S, Marches F, Gallegos 

M, Burton EC, Savino D, Hori T, Tanaka 

Y, Zurawski S, Zurawski G, Bover L, Liu 

YJ, Banchereau J, Palucka AK. Thymic 

stromal lymphopoietin fosters human 

breast tumor growth by promoting type 

2 inflammation. J Exp Med. 2011 Mar 

14;208(3):479–490. [PubMed: 21339324] 

Patent Status: U.S. Provisional 

Application No. 61/416,619 filed 

November 23, 2010 (HHS Reference No. 

E–019–2011/0–US–01) 

Licensing Status: Available for 

licensing. 

Licensing Contact: Patrick P. McCue, 

PhD; 301–435–5560; 

mccuepat@mail.nih.gov 

Collaborative Research Opportunity: 

The National Institute on Aging, 

Immunotherapeutics Unit, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize clinical application of 

TSLP in cancers. Please contact Nicole 

Guyton, PhD at 301–435–3101 or 

darackn@mail.nih.gov for more 

information. 

System and Method for Producing 

Nondiffracting Light Sheets That 

Improves the Performance of Selective 

Plane Illumination Microscopy (SPIM) 

Description of Technology: The 

technology offered for licensing relates 

to a system and method of producing 

nondiffracting beams of light that 

spatially overlap, but do not interfere 

with each other when intersecting the 

detection plane of an optical 

arrangement. The system includes an 

illumination source (i.e., ultrafast laser) 

for transmitting a beam of light through 

the optical arrangement that includes a 

diffraction grating for diffracting the 

light beam to produce beams of light 

having different wavelengths, which are 

then passed through an annular aperture 

that transforms the beams of light into 

nondiffracting beams having different 

wavelengths. The method can be readily 

utilized in Selective Plane Illumination 

Microscopy (SPIM), a system that 

provides optical sectioning of a sample 

that is labeled with fluorescent dyes. 

SPIM can provide quantitative threedimensional maps of the distribution of 

a flurophore within the sample with 

high spatiotemporal resolution and an 

excellent signal-to-noise ratio. The 

standard SPIM technique however 

produces nonuniform axial resolution, 

which is caused by the diffraction of the 

laser beam through the sample, causing 

degradation in the optical sectioning, 

and forcing a compromise between field 

of view and axial resolution. 

Techniques for decoupling field of view 

and axial resolution have previously 

utilized nondiffracting beams (e.g., 

Bessel beams) for sample illumination. 

The resulting interference from multiple 

nondiffracting beams degrades the 

quality of optical sectioning and the 

quality of the image. The present 

technology utilizing nondiffracting 

noninterfering beams is intended to 

alleviate the problems associated with 

the currently used SPIM techniques. 

Applications: In Selective Plane 

Illumination Microscopy (SPIM) used 

for optical sectioning and imaging of 

biological samples. 

Development Status: Proof of concept 

has been demonstrated. 

Inventors: Andrew York, Yicong Wu, 

Hari Shroff (NIBIB) 

Relevant Publications: 

1. Durnin J, Micheli J Jr, Eberly JH. 

Diffraction-free beams. Phys Rev Lett. 

1987 Apr 13;58(15):1499–1501. 

2. Greger K, Swoger J, Stelzer EH. Basic 

building units and properties of a 

fluorescence single plane illumination 

microscope. Rev Sci Instrum. 2007 

Feb;78(2):023705. [PubMed: 17578115] 

3. Fahrbach F, Rohrbach A. Microscopy with 

Non-diffracting Beams. Abstract at 2009 

Focus on Microscopy Conference, http:// 

www.focusonmicroscopy.org/2009/PDF/

28l_Fahrbach.pdf. 

4. Rohrbach A. Artifacts resulting from 

imaging in scattering media: a theoretical 

prediction. Opt Lett. 2009 Oct 

1;34(19):3041–3043. [PubMed: 

19794809] 

Patent Status: U.S. Provisional 

Application No. 61/360,352 filed 30 Jun 

2010, entitled ‘‘System and Method of 

Producing Nondiffracting Light Sheets 

by a Multiplicity of Spatially 

Overlapping, Minimally Interfering 

Nondiffracting Optical Beams’’ (HHS 

Reference No. E–118–2010/0–US–01) 

Licensing Status: Available for 

licensing. 

Licensing Contacts: 

• Uri Reichman, PhD, MBA; 301– 

435–4616; UR7a@nih.gov 

• Michael Shmilovich, Esq.; 301– 

435–5019; shmilovm@mail.nih.gov 

Collaborative Research Opportunity: 

The NIBIB Section on High Resolution 

Optical Imaging is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize the nondiffracting Light 

Sheets for SPIM. Please contact Hari 

Shroff at 301–435–1995 or 

hari.shroff@nih.gov for more 

information. 

Dated: April 14, 2011. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2011–9571 Filed 4–19–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Amended Notice of 

Meeting 

Notice is hereby given of a change in 

the meeting of the Board of Scientific 

Counselors, NIEHS, March 20, 2011, 7 

p.m. to March 22, 2011, 12:30 p.m., 

Doubletree Guest Suites, 2515 Meridian 

Parkway, Research Triangle Park, NC, 

27713 which was published in the 

Federal Register on February 23, 2011, 

76 FR 36. 

This Federal Register Notice has been 

amended to change the meeting date. 

The meeting will be held Sunday, May 

22, 2011 at 7 p.m. through Tuesday, 

May 24, 2011 at 12:30 p.m. The meeting 

is partially Closed to the public. 

Dated: April 12, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–9492 Filed 4–19–11; 8:45 am] 

BILLING CODE 4140–01–P 


srobinson on DSKHWCL6B1PROD with NOTICES